Skip to main content
SpringerLink
Log in
Book cover

St. John’s Wort and its Active Principles in Depression and Anxiety pp 99–121Cite as

Pharmacokinetics and biopharmaceuticals

  • Chapter

  • 1032 Accesses

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kasper S (2001) Hypericum perforatum — a review of clinical studies. Pharmacopsychiatry 34: 51–55

    Article  Google Scholar 

  2. Berner M, Riemann D, Berger M (2002) The Efficacy of SJW extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression. Eur Arch Psy Clin Neur 252(Suppl 1): 230

    Google Scholar 

  3. Laakmann G, Schüle C, Baghai T, Kieser M (1998) St. John’s Wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1): 54–55

    PubMed  Google Scholar 

  4. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998) Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 63: 499–510

    Article  PubMed  Google Scholar 

  5. Jensen AG, Hansen SH, Nielsen EO (2001) Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 68:1593–1605

    Article  PubMed  Google Scholar 

  6. Müller WE, Singer A, Wonnemann M (2001) Hyperforin-antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34(Suppl 1): S98–102

    Article  PubMed  Google Scholar 

  7. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 290: 1363–1368

    PubMed  Google Scholar 

  8. Wonnemann M, Singer A, Müller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John’s Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188–197

    Article  PubMed  Google Scholar 

  9. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T (2001) In vitro binding studies with two Hypericum perforatumextracts — hyperforin, hypericin and biapigenin — on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 34(Suppl 1): S45–48

    Article  PubMed  Google Scholar 

  10. Gobbi M, Valle FD, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, Caccia S, Cervo L, Mennini T (1999) Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 360: 262–269

    Article  PubMed  Google Scholar 

  11. Nöldner M, Schotz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 68: 577–580

    Article  PubMed  Google Scholar 

  12. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A (1998) Solubilized hypericin and pseudohy-pericin from Hypericum perforatum exert antidepressant activity in forced swimming test. Planta Med 64: 291–294

    PubMed  Google Scholar 

  13. Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (2003) Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: A pharmacokinetic study in rats. Planta Med 69: 189–192

    Article  PubMed  Google Scholar 

  14. Hänsel R, Keller K, Rimpler H, Schneider G (Hrsg) (1993) Hager’s Handbuch der Pharmazeutischen Praxis, Vol. 5. Springer Verlag, Berlin, Heidelberg, New York, 474–495

    Google Scholar 

  15. Hölzl J, Sattler S, Schütt H (1994) Johanniskraut: eine Alternative zu synthetischen Antidepressiva? Pharm Ztg 139: 3959–3977

    Google Scholar 

  16. Ostrowski E (1988) Untersuchung zur Analytik,14C-Markierung und Pharmakokinetik phenolischer Inhaltsstoffe von Hypericum perforatum L. Dissertation, Marburg, 118 ff

    Google Scholar 

  17. Biber A, Fischer H, Romer A, Chatterjee SS (1998) Oral bioavailability of Hypericum extracts in rats and humans. Pharmacopsychiatry 31(Suppl 1): 36–43

    Google Scholar 

  18. Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, Whale RWR, Cowen PJ (1999) Neuroendocrine evidence for dopaminergic actions of Hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 46: 581–584

    Article  PubMed  Google Scholar 

  19. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M (2001) Batch-to-batch reproducibility of St. John’s Wort preparations. Pharmacopsychiatry 34(Suppl 1): 151–156

    Google Scholar 

  20. Agrosi M, Mischiatti S, Harrasser PC, Savio D (2000) Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 7: 455–462

    PubMed  Google Scholar 

  21. Cui Y, Gurley B, Ang CYW, Leakey J (2002) Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 780: 129–135

    Google Scholar 

  22. Wonnemann M, Singer A, Siebert B, Müller WE (2001) Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John’s Wort. Pharmacopsychiatry 34: 148–151

    Google Scholar 

  23. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S (2002) Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 164: 423–428

    Article  PubMed  Google Scholar 

  24. Keller JH, Karas M, Müller WE, Volmer DA, Eckert GP, Abdel Tawab M, Blume HH, Dingermann T, Schubert-Zsilavecz M (2003) Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 75: 6084–6088

    PubMed  Google Scholar 

  25. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 3: 272–274

    Google Scholar 

  26. Demisch L, Hölzl J, Gollnik B, Kaczmarczyk P (1989) Identification of selective MAO-type A inhibition of Hypericum perforatum L. Pharmacopsychiatry 22: 194

    Google Scholar 

  27. Butterweck V, Korte B, Winterhoff H (2001) Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34(Suppl 1): 2–7

    Article  Google Scholar 

  28. Agostinis P, Vantieghem A, Merlevede W, de Witte PA (2002) Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 34: 221–241

    PubMed  Google Scholar 

  29. Lenard J, Rabson A, Vanderoef R (1993) Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci USA 90: 158–162

    PubMed  Google Scholar 

  30. Andersen DO, Weber ND, Wood SG, Hughes BG, Murray BK, North JA (1991) In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antivir Res 16: 185–196

    PubMed  Google Scholar 

  31. Liebes I, Mazur Y, Freeman D, Lavie D, Lavie B, Kudler N, Mendoza S, Levin B, Hochster H, Meruelo D (1991) A method for the quantification of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 195: 77–85

    PubMed  Google Scholar 

  32. Bauer S, Strömer E, Graubaum HJ, Roots I (2001) Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromatogr B 765: 29–35

    Google Scholar 

  33. Pirker R, Huck CW, Bonn GK (2002) Simultaneous determination of hypericin and hyperforin in human plasma and serum using liquid-liquid extraction, high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry. J Chromatogr B 777: 147–153

    Google Scholar 

  34. Kerb R, Brockmöller J, Staffeldt B, Ploch M, Roots I (1996) Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 40: 2087–2093

    PubMed  Google Scholar 

  35. Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I (1997) Hypericin and pseudohy-pericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30: 94–101

    PubMed  Google Scholar 

  36. Staffeldt B, Kerb B, Brockmöller J, Ploch M, Roots I (1994) Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 7(Suppl 1): 47–53

    Google Scholar 

  37. Weiser D (1991) Pharmakokinetic von Hypericin nach oraler Einnahme des Johanniskraut-Extraktes LI160. Nervenheilkunde 10: 318–319

    Google Scholar 

  38. Fox E, Murphy RF, McCully L, Adamson PC (2001) Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 47: 41–47

    PubMed  Google Scholar 

  39. Hertog MG, Feskens EJ, Kromhout D (1997) Antioxidant flavonols and coronary heart disease risk. Lancet 349: 699

    Google Scholar 

  40. Yochum L, Kushi L, Meyer K, Folsom A (1999) Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 149: 943–949

    PubMed  Google Scholar 

  41. Kiesewetter H, Koscielny J, Kalus U, Vix JM, Peil H, Petrini O, van Toor BS, de Mey C (2000) Efficacy of orally administered extract of red vine leaf AS 195 (Folia vitis viniferae) in chronic venous insufficiency (stages I–II): a randomized, double-blind, placebo-controlled trial. Arzneimittelforschung 50: 109–117

    PubMed  Google Scholar 

  42. Ihme N, Kiesewetter H, Jung F, Hoffmann KH, Birk A, Muller A, Grutzner KI (1997) Leg oedema protection from buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur J Clin Pharmacol 32: 427–436

    Google Scholar 

  43. Graefe EU, Wittig J, Mueller S, Riehtling AK, Uehleke B, Drewelow B, Pforte H, Jacobash G, Derendorf H, Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41: 492–499

    PubMed  Google Scholar 

  44. Erlund I, Alfthan G, Siren H, Arniemi K, Aro A (1999) Validated method for the quantitation of quercetin from human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B 727: 179–189

    Google Scholar 

  45. Erlund I, Kosonen T, Alfthan G, Mäenpää J, Perttunen K, Kenraali J, Parantainen J, Aro A (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56: 545–553

    PubMed  Google Scholar 

  46. Manach C, Morand C, Demigne C, Texier O, Regerat F, Remesy C (1997) Bioavailability of rutin and quercetin in rats. FEBS Lett 409: 12–16

    PubMed  Google Scholar 

  47. Hollman PCH, van Trijp JMP, Buysman NCP, v.d. Gaag MS, Mengelers MJB, de Vries JHM, Katan MB (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 418: 152–156

    PubMed  Google Scholar 

  48. Day A, Mellon F, Barron D, Sarrazin G, Morgan MRA, Williamson G (2001) Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free radic res 35: 941–952

    PubMed  Google Scholar 

  49. Wolffram S, Blöck M, Ader P (2002) Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J Nutr 132: 630–635

    PubMed  Google Scholar 

  50. Ishii K, Furuta T, Kasuya Y (2001) Determination of rutin in human plasma by high-performance liquid chromatography utilizing solid-phase extraction and ultraviolet detection. J Chromatogr B 759: 161–168

    Google Scholar 

  51. Cermak R, Landgraf S, Wolffram S (2003) The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J Nutr 133: 2802–2807

    PubMed  Google Scholar 

  52. O’Leary KA, Day AJ, Needs PW, Mellon FA, O’Brien NM, Williamson G (2003) Metabolism of quercetin-7-and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65: 479–491

    PubMed  Google Scholar 

  53. Lang F, Stumpf H. (1999) Considerations on future pharmacopoeial monographs for plant extracts. Pharmeuropa 11: 268–275

    Google Scholar 

  54. EMEA (1999) Note for guidance on specifications: Test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products. http://www.eudra.org/emea.html (Accessed June 2003)

    Google Scholar 

  55. Lang F, Keller K, Ihrig M, van Oudtshoorn-Eckard J, Möller H, Srinivasan S, He-ci Y (2003) Biopharmaceutical characterisation of herbal medicinal products. Pharm Forum 29: 1337–1346

    Google Scholar 

  56. Siewert M (1997) FIP guidelines for dissolution testing of solid oral products. Pharm Ind 59: 760–766

    Google Scholar 

  57. FDA Guidance for Industry (1997) Dissolution of immediate release solid oral dosage Forms. http://www.fda.gov/cder/guidance.html (Accessed June 2003)

    Google Scholar 

  58. Westerhoff K, Kaunzinger A, Wurglics M, Dressman J, Schubert-Zsilavecz M (2002) Biorelevant dissolution testing of St John’s Wort products. J Pharm Pharmacol 54: 1615–1621

    PubMed  Google Scholar 

  59. Schulte-Löbbert S, Westerhoff K, Wilke A, Schubert-Zsilavecz M, Wurglics M (2003) Development of a high-performance-liquid-chromatographic method for the determination of biapigenin in biorelevant media. J Pharm Biomed Anal 33: 53–60

    PubMed  Google Scholar 

  60. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB (1998) Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15: 698–705

    PubMed  Google Scholar 

  61. Beckert A, Quach T (1996) Improved hydrodynamics for apparatus 2. Dissolution Technologies 3

    Google Scholar 

  62. Shah V (2001) Dissolution: A quality control test versus a bioequivalence test. Dissolution Technologies 8: 6–7

    Google Scholar 

  63. Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15: 11–22

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmaceutical Chemistry, J.W. Goethe University Frankfurt/Main, Marie-Curie-Str. 9, D-60439, Frankfurt/Main, Germany

    Manfred Schubert-Zsilavecz

Authors
  1. Mario Wurglics
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manfred Schubert-Zsilavecz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut für Naturwissenschaftler, Biozentrum Universität Frankfurt, Marie-Curie-Str.9, 60439, Frankfurt, Germany

    Walter E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Wurglics, M., Schubert-Zsilavecz, M. (2005). Pharmacokinetics and biopharmaceuticals. In: Müller, W.E. (eds) St. John’s Wort and its Active Principles in Depression and Anxiety. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7338-5_9

Download citation

Publish with us

Policies and ethics

Search

Navigation